Jill Andersen Sells 37,256 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 37,256 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the completion of the sale, the insider owned 314,480 shares in the company, valued at $226,425.60. This trade represents a 10.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Tuesday, August 18th, Jill Andersen sold 30,706 shares of Invivyd stock. The stock was sold at an average price of $0.84, for a total transaction of $25,793.04.

Invivyd Trading Up 17.2%

Shares of Invivyd stock traded up $0.13 during mid-day trading on Tuesday, reaching $0.87. 7,732,095 shares of the stock were exchanged, compared to its average volume of 3,061,089. Invivyd, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $1.23.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The firm had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. Research analysts expect that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Invivyd

Large investors have recently bought and sold shares of the business. United Capital Financial Advisors LLC bought a new position in Invivyd in the second quarter valued at approximately $84,000. Bank of America Corp DE bought a new stake in shares of Invivyd during the 2nd quarter valued at $311,000. Jupiter Topco LLC bought a new stake in shares of Invivyd during the 2nd quarter valued at $30,048,000. ADAR1 Capital Management LLC acquired a new position in shares of Invivyd in the 2nd quarter valued at $3,322,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Invivyd in the 2nd quarter valued at $52,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IVVD has been the subject of a number of research reports. Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.